[Inflammatory diseases of the intestines].
5-aminosalicylates preparations are not superior to placebo for the maintenance of medically-induced remission in patients with Crohn's disease. We have to reconsider the potential risks associated with inhibition of lymphocyte trafficking since it can induce serious and potentially lethal infections. Infliximab has shown efficacy in active ulcerative colitis.
Felley
C
C
Service de gastro-entérologie et hépatologie, CHUV, 1011 Lausanne.
Guyot
J
J
Hess
J
J
Mottet
C
C
Delarive
J
J
Michetti
P
P
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000276:immunology*; D003424:Crohn Disease / Q000188:drug therapy* / Q000276:immunology*; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006801:Humans; D000069285:Infliximab; D019804:Mesalamine / Q000627:therapeutic use; D012307:Risk Factors
D000305:Adrenal Cortex Hormones; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D019804:Mesalamine; D000069285:Infliximab